EVMN Evommune, Inc. Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
12:14
Aug 26
DeItaone Twitter news aggregator (Walter Bloomberg)
News wire reports multiple price target cuts across a broad set of stocks including DKS, INTU.
News wire reports multiple price target cuts across a broad set of stocks including DKS, INTU, and SYRE, alongside new coverage initiations and resumptions from various analysts.
EVMN
12:52
Aug 17
seedy19tron Biotech trader, L/S
Reports most closed positions across funds
"Reports most closed positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
EVMN
MED
11:57
Aug 17
seedy19tron Biotech trader, L/S
Reports most closed positions by specialist funds
Reports the most closed positions by specialist funds in Q2 2026, excluding M&A takeouts.
EVMN
MED
13:52
Jun 29
Martin Shkreli Investor / Podcast host
Buy EVMN on the dip following a drug failure, as the overhang clears and market attention can.
Buy EVMN on the dip following a drug failure, as the overhang clears and market attention can now re-rate the IL-18 program, a potentially differentiated asset in the autoimmune space.
EVMN 1ST
HIGH

About EVMN Analyst Coverage

Buzzberg tracks EVMN (Evommune, Inc.) across 3 sources. 1 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (25%). 4 total trade ideas tracked. Latest voices: DeItaone, seedy19tron, Martin Shkreli.